{"product_id":"sxtp-pestle-analysis","title":"(SXTP) 60 Degrees Pharmaceuticals, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis 60 Degrees Pharmaceuticals, Inc. PESTLE Analysis outlines political, economic, social, technological, legal, and environmental factors affecting the company and why they matter. This page shows a real preview of the report so you can judge style and depth; purchase the full version to receive the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWashington, D.C. headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., giving it close access to HHS, FDA, NIH, and Congress. That helps the Company track U.S. public health priorities, funding shifts, and drug-policy changes in real time. For an infectious-disease Company, that federal proximity can speed regulatory visibility and government-facing engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA-controlled drug access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArakoda is 60 Degrees Pharmaceuticals, Inc.’s FDA-approved malaria prophylaxis in the U.S., so current sales depend on a single cleared product. Any broader revenue lift still hinges on FDA clinical trials and review for the rest of the pipeline, which can take years and add heavy costs. That makes stable policy, clear trial standards, and predictable regulator expectations central to the business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfectious-disease priority areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. focuses on infections that sit close to public health surveillance, and that makes federal outbreak attention a real catalyst for development. WHO reported 263 million malaria cases and 597,000 deaths in 2023, while dengue and other respiratory outbreaks kept agencies on alert. That policy focus can speed trial interest, funding, and review paths for drugs like ARAKODA and its wider pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. public health funding climate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eU.S. public health funding still supports specialty anti-infective work when it maps to preparedness and unmet need. NIH’s budget is near $48 billion in FY2025, so programs tied to emerging viruses and tropical diseases can gain grant, trial, and partnership attention, which lifts 60 Degrees Pharmaceuticals, Inc.’s visibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePreparedness funding favors anti-infectives.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTropical disease programs fit public priorities.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eGrant access can improve market reach.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial geography\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. runs development from a U.S. base, so trial timing hinges on FDA and other U.S. policy choices. The FDA’s IND review clock is 30 days, but protocol changes, site clearances, and political shifts can still slow enrollment and push out commercialization. For a small biopharma, even a few months’ delay can hit cash burn and launch timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. policy stability matters for trial speed\u003c\/li\u003e\n\u003cli\u003eFDA review clock: 30 days\u003c\/li\u003e\n\u003cli\u003eDelays can lift burn and defer sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Policy and NIH Funding Shape 60 Degrees Pharma’s Outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eU.S. policy matters a lot for 60 Degrees Pharmaceuticals, Inc.: it sits near FDA, NIH, HHS, and Congress, so it can track public-health funding and rule changes fast. Its Arakoda sales still depend on one FDA-approved product, and new pipeline value needs longer FDA review. NIH’s FY2025 budget is about $48 billion, which keeps tropical-disease work in reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolitical factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH FY2025 budget\u003c\/td\u003e\n\u003ctd\u003e~$48 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA IND review\u003c\/td\u003e\n\u003ctd\u003e30 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps the key Political, Economic, Social, Technological, Environmental, and Legal forces shaping 60 Degrees Pharmaceuticals, Inc.’s market outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise 60 Degrees Pharmaceuticals PESTLE snapshot that quickly clarifies external risks for faster planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable list of primary industry reports, government datasets, and benchmarks to speed due diligence and validate 60 Degrees Pharmaceuticals’ key assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle approved product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. relies on one approved commercial asset, Arakoda, so revenue is tied to a single product rather than a broad drug portfolio. That makes cash flow more exposed than larger diversified drug makers, where multiple launches can offset weak sales in one line. Longer-term value still hinges on pipeline conversion into approved, revenue-producing products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D-intensive cost base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase IIb and Phase IIA programs force 60 Degrees Pharmaceuticals, Inc. to keep funding clinical work before wider sales can scale, so R\u0026amp;D stays the main cost driver. For small specialty pharma firms, cash burn often runs ahead of revenue, which makes liquidity and financing timing critical. Tight financing discipline can decide whether the pipeline keeps moving or slows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple pre-commercial assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTafenoquine and Celgosivir remain investigational, so 60 Degrees Pharmaceuticals, Inc. has no guaranteed near-term product sales from them yet. Their economic value now rests on clinical success, regulatory approval, and market entry, not current revenue. That means the upside can be large, but the risk of failure is still high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnered asset development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Tufts Medical Center license agreement gives 60 Degrees Pharmaceuticals, Inc. a lower-cost path to advance tafenoquine in babesiosis, which matters for a small company with limited cash. By sharing scientific and development risk, partnerships can stretch each R\u0026amp;D dollar farther and protect capital for other programs. That is a big advantage when clinical work can cost millions before any revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTufts support lowers direct development burden\u003c\/li\u003e\n\u003cli\u003eRisk is shared across partners\u003c\/li\u003e\n\u003cli\u003eCapital efficiency improves for a small issuer\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNiche infectious-disease market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. sells specialty anti-infectives like ARAKODA, not broad primary-care drugs, so its market is narrow but can support higher pricing when clinical value is clear. Niche infectious-disease demand stays limited versus mass categories, which caps volume even if margins are better. For example, WHO still tracks malaria as a major global disease, but the prophylaxis market is much smaller than common chronic-disease drug markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eSpecialty drugs can price higher.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eDemand stays capped by niche use.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eClinical benefit drives payer uptake.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e60 Degrees’ Cash Flow Hinges on ARAKODA, R\u0026amp;D, and Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. has one marketed product, so cash flow still depends on ARAKODA and stays sensitive to sales swings. Clinical work for tafenoquine and celgosivir keeps R\u0026amp;D spend high, while Tufts support helps limit cash burn. That mix makes financing timing and partner funding key to survival. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eEconomic factor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-product sales\u003c\/td\u003e\n\u003ctd\u003eHigh revenue concentration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eHeavy cash use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTufts license\u003c\/td\u003e\n\u003ctd\u003eLower funding burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003e60 Degrees Pharmaceuticals, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for evaluating 60 Degrees Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTravel malaria prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTravel malaria prevention matters because Arakoda targets prophylaxis for travelers and exposed populations. WHO estimated 263 million malaria cases and 597,000 deaths in 2023, so risk awareness before travel can lift prevention demand. Patient education on dosing, timing, and adherence is key to adoption and better use of prophylaxis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnmet need in rare infections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBabesiosis, fungal pneumonias, and candidiasis still leave real treatment gaps; invasive candidiasis can carry mortality near 40%, and fungal pneumonias like invasive aspergillosis often exceed 30% to 50% in high-risk patients. Babesiosis remains uncommon but meaningful, with about 1,500 to 2,000 U.S. cases reported each year. In small specialty markets, clear efficacy can still drive strong uptake because patients and clinicians have few good options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-COVID infection awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePost-COVID infection awareness helped 60 Degrees Pharmaceuticals, Inc. make the tafenoquine Phase IIb COVID-19 study easier to explain to clinicians and investors. After 2020, clinical trial participation and antiviral R\u0026amp;D drew far more public attention, with more than 1 million U.S. adults enrolled in NIH clinical studies by 2025. That visibility can lower adoption friction for infection-focused innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVector-borne disease concern\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZika and dengue stay socially important because outbreaks and travel exposure keep them visible; WHO reported dengue surged to over 14 million cases globally in 2024, with nearly 12,000 severe cases. Public concern rises fast when local mosquito risk spikes, which can lift attention to prevention and treatment options for 60 Degrees Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutbreaks drive awareness fast.\u003c\/li\u003e\n\u003cli\u003eTravel exposure keeps risk high.\u003c\/li\u003e\n\u003cli\u003eRising concern supports solution demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinician adoption matters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinician adoption is a key gatekeeper for 60 Degrees Pharmaceuticals, Inc. because infectious disease, travel medicine, and hospital prescribers shape uptake of its malaria products. Specialty drugs need clear clinical differentiation, and in a market with only a few prevention options, trust comes from medical education plus real-world use. That matters even more when treatment decisions depend on specialist opinion and experience, not mass-market demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eSpecialists drive prescribing.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eClear differentiation builds trust.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eReal-world evidence supports uptake.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMalaria and Dengue Awareness Could Lift 60 Degrees Pharmaceuticals Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAwareness of malaria, dengue, and travel-related infection risk supports demand for 60 Degrees Pharmaceuticals, Inc., especially when WHO still counted 263 million malaria cases and 597,000 deaths in 2023 and dengue topped 14 million cases in 2024. Specialist prescribing also matters because adoption depends on clinician trust, patient education, and real-world use in small, high-need markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria\u003c\/td\u003e\n\u003ctd\u003e263M cases; 597k deaths\u003c\/td\u003e\n\u003ctd\u003eRaises prevention demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDengue\u003c\/td\u003e\n\u003ctd\u003e14M+ cases in 2024\u003c\/td\u003e\n\u003ctd\u003eBoosts outbreak awareness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist uptake\u003c\/td\u003e\n\u003ctd\u003eClinician-led\u003c\/td\u003e\n\u003ctd\u003eDrives prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArakoda formulation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArakoda is 60 Degrees Pharmaceuticals, Inc.'s approved tafenoquine regimen, and its differentiated tablet platform supports once-weekly malaria prophylaxis, which helps dosing convenience versus daily options. In 2025, the company reported revenue of about $3.8 million, so product fit and adherence matter. The same formulation base also gives 60 Degrees Pharmaceuticals, Inc. a launch point for related tafenoquine programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase IIb tafenoquine study\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. is testing tafenoquine in Phase IIb for potential COVID-19 use, and this mid-stage step is where safety and early efficacy data can make or break the program. If the results are positive, they can support later-stage trials and open partnering talks, which is critical for a small biotech with limited capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase IIA multi-indication pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTafenoquine is being tested in Phase IIA across 3 indications: babesiosis, fungal pneumonias, and candidiasis. This one-molecule, repurposing approach can cut development time versus finding a new drug from scratch. For 60 Degrees Pharmaceuticals, Inc., that also spreads clinical risk across multiple shots on goal from the same asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCelgosivir antiviral development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCelgosivir shows 60 Degrees Pharmaceuticals, Inc.’s platform bet on antivirals: it is being developed for Zika, respiratory viruses, and dengue fever, so the drug must clear strong translational and clinical testing hurdles. WHO reported over 10 million dengue cases in 2024, which keeps the addressable need real. \u003c\/p\u003e\n\u003cp\u003eThis broad use case can widen optionality, but it also raises the bar on proof of efficacy across different viruses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform approach, not one-disease focus\u003c\/li\u003e\n\u003cli\u003eNeeds multi-indication clinical data\u003c\/li\u003e\n\u003cli\u003eDengue demand is still high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTufts Medical Center collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc.’s patent license agreement with Tufts Medical Center supports tafenoquine work for babesiosis prevention and treatment. That matters because babesiosis remains an unmet need in the U.S., with CDC reporting about 2,000 cases a year, and academic input can speed disease-specific design, safety work, and trial strategy without building every capability in-house.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTufts adds clinical expertise.\u003c\/li\u003e\n\u003cli\u003eSupports tafenoquine development.\u003c\/li\u003e\n\u003cli\u003eTargets babesiosis unmet need.\u003c\/li\u003e\n\u003cli\u003eLowers internal R\u0026amp;D burden.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e60 Degrees’ Value Hinges on Tafenoquine, Trial Wins, and Fast Clinical Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTechnological risk for 60 Degrees Pharmaceuticals, Inc. is concentrated in tafenoquine and celgosivir, so trial outcomes and formulation performance drive value. The company reported about $3.8 million in 2025 revenue, making fast clinical proof important. A weekly Arakoda dose helps adherence, and the Tufts license adds outside disease expertise for babesiosis.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003eAbout $3.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArakoda dosing\u003c\/td\u003e\n\u003ctd\u003eOnce weekly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBabesiosis burden\u003c\/td\u003e\n\u003ctd\u003eAbout 2,000 U.S. cases\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved Arakoda product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc.'s Arakoda is an FDA-approved atovaquone\/ proguanil product, so it must meet U.S. labeling, safety, quality, and post-market surveillance rules. Approval also brings ongoing pharmacovigilance and promotion limits under FDA oversight, including adverse-event reporting and cGMP compliance. It is a regulated commercial asset with a U.S. market authorization first cleared in 2018.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestigational drug status\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. still depends on investigational programs: Tafenoquine and Celgosivir are unapproved for most uses, so they stay under clinical-trial rules rather than broad marketing rights. That means formal FDA oversight, IRB review, and strict protocol compliance at every step.\u003c\/p\u003e\n\u003cp\u003eLegal risk climbs fast if trial conduct, safety reporting, or investor disclosures miss the mark. A single protocol breach can trigger a clinical hold, delay data readouts, or weaken future labeling and partnership talks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent license agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. has a patent license agreement with Tufts Medical Center that gives it rights to develop and commercialize specific tafenoquine uses. That license is the legal base for its babesiosis work, which is still an unmet need in the U.S.; CDC data show babesiosis cases remain concentrated in the Northeast and Upper Midwest. Any breach, expiry, or royalty issue could slow the program and hurt revenue plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. must run Phase IIb and Phase IIA trials under strict GCP rules, with informed consent, safety reporting, and clean data trails. Any delay or protocol breach can slow FDA review and weaken approval odds. This matters because small trial programs have little room for error, so one compliance miss can hit both timeline and valuation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsent must be documented.\u003c\/li\u003e\n\u003cli\u003eAdverse events need fast reporting.\u003c\/li\u003e\n\u003cli\u003eData integrity supports approval.\u003c\/li\u003e\n\u003cli\u003eDelays can cut approval odds.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct liability exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. faces product-liability risk if anti-infectives trigger adverse events or if warnings miss rare harms. That risk is sharper in prophylaxis and multi-use settings, where exposure is longer and patient counts are broader. Strong adverse-event tracking, label updates, and trial documentation are key to limiting claims.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher risk in prophylaxis use\u003c\/li\u003e\n\u003cli\u003eClaims often cite warning gaps\u003c\/li\u003e\n\u003cli\u003eMonitor adverse events closely\u003c\/li\u003e\n\u003cli\u003eKeep records for every indication\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e60 Degrees Pharma’s Legal Risks: FDA, Trial, and IP Exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegal risk at 60 Degrees Pharmaceuticals, Inc. is centered on FDA compliance, trial conduct, and IP rights. Arakoda’s U.S. approval means ongoing cGMP, labeling, and adverse-event reporting duties, while Tafenoquine and Celgosivir stay under clinical-trial rules. Any breach can delay review, trigger holds, or weaken value. The Tufts license is key for tafenoquine rights.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal item\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArakoda\u003c\/td\u003e\n\u003ctd\u003eFDA post-market duties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTafenoquine\u003c\/td\u003e\n\u003ctd\u003eTrial and IRB compliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTufts license\u003c\/td\u003e\n\u003ctd\u003eRoyalty or expiry risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClimate-linked vector diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMalaria, Zika, and dengue track mosquito exposure, so rain, heat, and humidity can quickly change case counts. WHO estimated 263 million malaria cases and 597,000 deaths in 2023, while the Americas saw a record 12.6 million dengue cases in 2024. For 60 Degrees Pharmaceuticals, that makes prevention and treatment demand highly seasonal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal warming and range shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWarming temperatures are pushing insect vectors into new areas, which can widen the market for 60 Degrees Pharmaceuticals, Inc. but also shift where its anti-infective products matter most. WHO said dengue topped 14 million cases globally in 2024, showing how fast climate-linked vector risk can scale. That makes adaptable public health response and flexible demand planning critical as range shifts change outbreak patterns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTravel and outbreak exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTravel, rainy seasons, and regional outbreaks lift infection risk, and WHO said malaria caused 263 million cases and 597,000 deaths in 2023. That backdrop supports 60 Degrees Pharmaceuticals, Inc.’s focus on prophylaxis and treatment, since demand often rises when exposure rises. When weather or mobility spreads disease, market need can follow fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLaboratory and clinical waste controls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDrug development at 60 Degrees Pharmaceuticals, Inc. relies on biological samples and regulated clinical waste, so lab controls must cover segregation, labeling, transport, and disposal. In the U.S., this sits under EPA hazardous-waste rules and OSHA biosafety duties, so weak handling can raise spill, infection, and permit risk fast. Compliance also protects the brand with regulators, sites, and trial partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSegregate biohazard and chemical waste\u003c\/li\u003e\n\u003cli\u003eUse approved transport and disposal vendors\u003c\/li\u003e\n\u003cli\u003eTrack waste logs and chain of custody\u003c\/li\u003e\n\u003cli\u003eReduce spill, safety, and reputational risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chain weather risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. depends on stable sourcing, cold-chain storage, and on-time transport, so severe weather can quickly delay trial supplies and finished product shipments. With limited backup vendors and little inventory cushion, even one storm can interrupt site dosing, customs clearance, or distribution. The risk is higher for a small specialty pharma name because recovery time is longer and cash burn can rise fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeather can stop shipments.\u003c\/li\u003e\n\u003cli\u003eTrials need steady supply.\u003c\/li\u003e\n\u003cli\u003eSmall firms have less redundancy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWeather and outbreaks drive volatile demand for 60 Degrees Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRain, heat, and humidity drive mosquito spread, so 60 Degrees Pharmaceuticals, Inc. faces demand swings tied to weather and outbreaks. WHO reported 263 million malaria cases and 597,000 deaths in 2023, and the Americas logged 12.6 million dengue cases in 2024. Climate shift can expand risk areas, but it also makes planning harder.\u003c\/p\u003e\n\u003cp\u003eStorms and weak logistics can delay trial supplies, cold-chain storage, and product deliveries, which is a bigger issue for a small specialty pharma with limited backup vendors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria cases\u003c\/td\u003e\n\u003ctd\u003e263 million in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria deaths\u003c\/td\u003e\n\u003ctd\u003e597,000 in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDengue cases\u003c\/td\u003e\n\u003ctd\u003e12.6 million in the Americas, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235119767817,"sku":"sxtp-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sxtp-pestle-analysis.webp?v=1785733020","url":"https:\/\/dcfanalyst.com\/products\/sxtp-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}